Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Correlations Between Patient-Reported Outcomes and Clinical Responses in the Phase 3 Clinical Trials POETYK PSO-1 and POETYK PSO-2
Skin(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要